TreeWAS – Variant ID: rs72739921

Hospitalization Episode Statistics (HES)

Self-Reported Statistics (SRS)

Hierarchical visualisation How to interpret this figure?

Click here to show this figure without filtering.

Click on a node to zoom (except terminal nodes).

Download this figure in format

Results table

Term	Risk posterior probability	No effect posterior probability	Protective posterior probability
E87 Other disorders of fluid, electrolyte and acid-base balance	0.019	0.981	0.000
E87.7 Fluid overload	0.019	0.981	0.000
E87.5 Hyperkalaemia	0.018	0.982	0.000
E87.3 Alkalosis	0.017	0.983	0.000
E87.6 Hypokalaemia	0.017	0.983	0.000
E87.8 Other disorders of electrolyte and fluid balance, not elsewhere classified	0.017	0.983	0.000
E87.0 Hyperosmolality and hypernatraemia	0.015	0.985	0.000
E87.1 Hypo-osmolality and hyponatraemia	0.015	0.985	0.000
E87.4 Mixed disorder of acid-base balance	0.014	0.986	0.000
S01.3 Open wound of ear	0.000	0.988	0.012
E86 Volume depletion	0.010	0.990	0.000
E70-E90 Metabolic disorders	0.009	0.991	0.000
E73 Lactose intolerance	0.008	0.992	0.000
J22 Unspecified acute lower respiratory infection	0.008	0.992	0.000
E79 Disorders of purine and pyrimidine metabolism	0.007	0.993	0.000
S01.4 Open wound of cheek and temporomandibular area	0.000	0.993	0.007
E84 Cystic fibrosis	0.007	0.993	0.000
N60.8 Other benign mammary dysplasias	0.007	0.993	0.000
C05 Malignant neoplasm of palate	0.007	0.993	0.000
E73.9 Lactose intolerance, unspecified	0.007	0.993	0.000
C00-C14 Malignant neoplasms of lip, oral cavity and pharynx	0.007	0.993	0.000
E88 Other metabolic disorders	0.007	0.993	0.000
E77 Disorders of glycoprotein metabolism	0.007	0.993	0.000
E76 Disorders of glycosaminoglycan metabolism	0.007	0.993	0.000
E75 Disorders of sphingolipid metabolism and other lipid storage disorders	0.007	0.993	0.000
E72 Other disorders of amino-acid metabolism	0.007	0.993	0.000
E71 Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism	0.007	0.993	0.000
E70 Disorders of aromatic amino-acid metabolism	0.007	0.993	0.000
E90 Nutritional and metabolic disorders in diseases classified elsewhere	0.007	0.993	0.000
E74 Other disorders of carbohydrate metabolism	0.007	0.993	0.000
E79.0 Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease	0.006	0.993	0.000
C09 Malignant neoplasm of tonsil	0.006	0.993	0.000
C01 Malignant neoplasm of base of tongue	0.006	0.993	0.000
C09.9 Tonsil, unspecified	0.006	0.994	0.000
C02 Malignant neoplasm of other and unspecified parts of tongue	0.006	0.994	0.000
C05.1 Soft palate	0.006	0.994	0.000
N60.9 Benign mammary dysplasia, unspecified	0.006	0.994	0.000
C05.0 Hard palate	0.006	0.994	0.000
E80 Disorders of porphyrin and bilirubin metabolism	0.006	0.994	0.000
E87.2 Acidosis	0.006	0.994	0.000
N60 Benign mammary dysplasia	0.006	0.994	0.000
C10 Malignant neoplasm of oropharynx	0.006	0.994	0.000
E84.9 Cystic fibrosis, unspecified	0.006	0.994	0.000
E73.8 Other lactose intolerance	0.006	0.994	0.000
E73.1 Secondary lactase deficiency	0.006	0.994	0.000
E73.0 Congenital lactase deficiency	0.006	0.994	0.000
Y40.0 Penicillins	0.006	0.994	0.000
C05.9 Palate, unspecified	0.006	0.994	0.000
E79.9 Disorder of purine and pyrimidine metabolism, unspecified	0.005	0.994	0.000
E79.8 Other disorders of purine and pyrimidine metabolism	0.005	0.994	0.000
E79.1 Lesch-Nyhan syndrome	0.005	0.994	0.000
J94.2 Haemothorax	0.006	0.994	0.000
C02.4 Lingual tonsil	0.006	0.994	0.000
N60.4 Mammary duct ectasia	0.006	0.994	0.000
C13 Malignant neoplasm of hypopharynx	0.005	0.994	0.000
S01 Open wound of head	0.000	0.994	0.006
C08 Malignant neoplasm of other and unspecified major salivary glands	0.005	0.994	0.000
Z96.7 Presence of other bone and tendon implants	0.006	0.994	0.000
C12 Malignant neoplasm of pyriform sinus	0.005	0.995	0.000
E88.1 Lipodystrophy, not elsewhere classified	0.005	0.995	0.000
E84.8 Cystic fibrosis with other manifestations	0.005	0.995	0.000
E84.1 Cystic fibrosis with intestinal manifestations	0.005	0.995	0.000
E84.0 Cystic fibrosis with pulmonary manifestations	0.005	0.995	0.000
E80.1 Porphyria cutanea tarda	0.005	0.995	0.000
C02.1 Border of tongue	0.005	0.995	0.000
C06 Malignant neoplasm of other and unspecified parts of mouth	0.005	0.995	0.000
T78.4 Allergy, unspecified	0.005	0.995	0.000
Y40 Systemic antibiotics	0.005	0.995	0.000
C10.9 Oropharynx, unspecified	0.005	0.995	0.000
C03 Malignant neoplasm of gum	0.005	0.995	0.000
C05.8 Overlapping lesion of palate	0.005	0.995	0.000
C05.2 Uvula	0.005	0.995	0.000
E88.8 Other specified metabolic disorders	0.005	0.995	0.000
C11 Malignant neoplasm of nasopharynx	0.005	0.995	0.000
C00 Malignant neoplasm of lip	0.005	0.995	0.000
C02.9 Tongue, unspecified	0.005	0.995	0.000
E85 Amyloidosis	0.005	0.995	0.000
E88.9 Metabolic disorder, unspecified	0.005	0.995	0.000
E88.3 Tumour lysis syndrome	0.005	0.995	0.000
M54.36 Sciatica (Lumbar region)	0.005	0.995	0.000
E70.9 Disorder of aromatic amino-acid metabolism, unspecified	0.005	0.995	0.000
E70.8 Other disorders of aromatic amino-acid metabolism	0.005	0.995	0.000
E70.3 Albinism	0.005	0.995	0.000
E70.2 Disorders of tyrosine metabolism	0.005	0.995	0.000
E70.1 Other hyperphenylalaninaemias	0.005	0.995	0.000
E70.0 Classical phenylketonuria	0.005	0.995	0.000
E71.3 Disorders of fatty-acid metabolism	0.005	0.995	0.000
E71.2 Disorder of branched-chain amino-acid metabolism, unspecified	0.005	0.995	0.000
E71.1 Other disorders of branched-chain amino-acid metabolism	0.005	0.995	0.000
E71.0 Maple-syrup-urine disease	0.005	0.995	0.000
E72.9 Disorder of amino-acid metabolism, unspecified	0.005	0.995	0.000
E72.8 Other specified disorders of amino-acid metabolism	0.005	0.995	0.000
E72.5 Disorders of glycine metabolism	0.005	0.995	0.000
E72.4 Disorders of ornithine metabolism	0.005	0.995	0.000
E72.3 Disorders of lysine and hydroxylysine metabolism	0.005	0.995	0.000
E72.2 Disorders of urea cycle metabolism	0.005	0.995	0.000
E72.1 Disorders of sulphur-bearing amino-acid metabolism	0.005	0.995	0.000
E72.0 Disorders of amino-acid transport	0.005	0.995	0.000
E75.6 Lipid storage disorder, unspecified	0.005	0.995	0.000
E75.5 Other lipid storage disorders	0.005	0.995	0.000
E75.4 Neuronal ceroid lipofuscinosis	0.005	0.995	0.000
E75.3 Sphingolipidosis, unspecified	0.005	0.995	0.000
E75.2 Other sphingolipidosis	0.005	0.995	0.000
E75.1 Other gangliosidosis	0.005	0.995	0.000
E75.0 GM2 gangliosidosis	0.005	0.995	0.000
E76.9 Disorder of glucosaminoglycan metabolism, unspecified	0.005	0.995	0.000
E76.8 Other disorders of glucosaminoglycan metabolism	0.005	0.995	0.000
E76.3 Mucopolysaccharidosis, unspecified	0.005	0.995	0.000
E76.2 Other mucopolysaccharidoses	0.005	0.995	0.000
E76.1 Mucopolysaccharidosis, type II	0.005	0.995	0.000
E76.0 Mucopolysaccharidosis, type I	0.005	0.995	0.000
E77.9 Disorder of glycoprotein metabolism, unspecified	0.005	0.995	0.000
E77.8 Other disorders of glycoprotein metabolism	0.005	0.995	0.000
E77.1 Defects in glycoprotein degradation	0.005	0.995	0.000
E77.0 Defects in posttranslational modification of lysosomal enzymes	0.005	0.995	0.000
E74.9 Disorder of carbohydrate metabolism, unspecified	0.005	0.995	0.000
E74.8 Other specified disorders of carbohydrate metabolism	0.005	0.995	0.000
E74.4 Disorders of pyruvate metabolism and gluconeogenesis	0.005	0.995	0.000
E74.2 Disorders of galactose metabolism	0.005	0.995	0.000
E74.1 Disorders of fructose metabolism	0.005	0.995	0.000
E74.0 Glycogen storage disease	0.005	0.995	0.000
E88.0 Disorders of plasma-protein metabolism, not elsewhere classified	0.005	0.995	0.000
E74.3 Other disorders of intestinal carbohydrate absorption	0.005	0.995	0.000
S01.1 Open wound of eyelid and periocular area	0.000	0.995	0.005
C09.8 Overlapping lesion of tonsil	0.005	0.995	0.000
C09.1 Tonsillar pillar (anterior) (posterior)	0.005	0.995	0.000
C09.0 Tonsillar fossa	0.005	0.995	0.000
E80.2 Other porphyria	0.005	0.995	0.000
E88.2 Lipomatosis, not elsewhere classified	0.005	0.995	0.000
C02.8 Overlapping lesion of tongue	0.005	0.995	0.000
C02.3 Anterior two-thirds of tongue, part unspecified	0.005	0.995	0.000
C02.0 Dorsal surface of tongue	0.005	0.995	0.000
C02.2 Ventral surface of tongue	0.005	0.995	0.000
Y40.1 Cefalosporins and other -lactam antibiotics	0.005	0.995	0.000
S01.2 Open wound of nose	0.000	0.995	0.005
C13.9 Hypopharynx, unspecified	0.005	0.995	0.000
R80 Isolated proteinuria	0.005	0.995	0.000
T78 Adverse effects, not elsewhere classified	0.005	0.995	0.000
E89 Postprocedural endocrine and metabolic disorders, not elsewhere classified	0.005	0.995	0.000
C08.9 Major salivary gland, unspecified	0.005	0.995	0.000
E80.7 Disorder of bilirubin metabolism, unspecified	0.004	0.995	0.000
E80.6 Other disorders of bilirubin metabolism	0.004	0.995	0.000
E80.5 Crigler-Najjar syndrome	0.004	0.995	0.000
E80.3 Defects of catalase and peroxydase	0.004	0.995	0.000
E80.0 Hereditary erythropoietic porphyria	0.004	0.995	0.000
N60.2 Fibroadenosis of breast	0.005	0.995	0.000
S01.9 Open wound of head, part unspecified	0.000	0.995	0.005
M54.96 Dorsalgia, unspecified (Lumbar region)	0.005	0.995	0.000
N60.1 Diffuse cystic mastopathy	0.005	0.995	0.000
C10.8 Overlapping lesion of oropharynx	0.004	0.995	0.000
C10.4 Branchial cleft	0.004	0.995	0.000
C10.3 Posterior wall of oropharynx	0.004	0.995	0.000
C10.2 Lateral wall of oropharynx	0.004	0.995	0.000
C10.1 Anterior surface of epiglottis	0.004	0.995	0.000
C10.0 Vallecula	0.004	0.995	0.000
C04 Malignant neoplasm of floor of mouth	0.004	0.995	0.000
T78.1 Other adverse food reactions, not elsewhere classified	0.004	0.996	0.000
C14 Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx	0.004	0.996	0.000
Y40.7 Antifungal antibiotics, systemically used	0.004	0.996	0.000
Y40.5 Aminoglycosides	0.004	0.996	0.000
T78.8 Other adverse effects, not elsewhere classified	0.004	0.996	0.000
Y40.3 Macrolides	0.004	0.996	0.000
N60.3 Fibrosclerosis of breast	0.004	0.996	0.000
Y40.6 Rifamycins	0.004	0.996	0.000
C13.8 Overlapping lesion of hypopharynx	0.004	0.996	0.000
C13.2 Posterior wall of hypopharynx	0.004	0.996	0.000
C13.1 Aryepiglottic fold, hypopharyngeal aspect	0.004	0.996	0.000
C13.0 Postcricoid region	0.004	0.996	0.000
Y40.8 Other systemic antibiotics	0.004	0.996	0.000
C06.2 Retromolar area	0.004	0.996	0.000
C08.8 Overlapping lesion of major salivary glands	0.004	0.996	0.000
C08.1 Sublingual gland	0.004	0.996	0.000
C08.0 Submandibular gland	0.004	0.996	0.000
T78.2 Anaphylactic shock, unspecified	0.004	0.996	0.000
C06.0 Cheek mucosa	0.004	0.996	0.000
T83.8 Other complications of genito-urinary prosthetic devices, implants and grafts	0.004	0.996	0.000
C03.1 Lower gum	0.004	0.996	0.000
G25.0 Essential tremor	0.004	0.996	0.000
C06.8 Overlapping lesion of other and unspecified parts of mouth	0.004	0.996	0.000
C06.1 Vestibule of mouth	0.004	0.996	0.000
Y40.4 Tetracyclines	0.004	0.996	0.000
Y40.2 Chloramphenicol group	0.004	0.996	0.000
G25 Other extrapyramidal and movement disorders	0.004	0.996	0.000
M54.9 Dorsalgia, unspecified	0.004	0.996	0.000
C03.9 Gum, unspecified	0.004	0.996	0.000
C03.0 Upper gum	0.004	0.996	0.000
E85.3 Secondary systemic amyloidosis	0.004	0.996	0.000
M54.98 Dorsalgia, unspecified (Sacral and sacrococcygeal region)	0.004	0.996	0.000
G31.8 Other specified degenerative diseases of nervous system	0.004	0.996	0.000
C00.9 Lip, unspecified	0.004	0.996	0.000
C00.8 Overlapping lesion of lip	0.004	0.996	0.000
C00.6 Commissure of lip	0.004	0.996	0.000
C00.5 Lip, unspecified, inner aspect	0.004	0.996	0.000
C00.4 Lower lip, inner aspect	0.004	0.996	0.000
C00.3 Upper lip, inner aspect	0.004	0.996	0.000
C00.2 External lip, unspecified	0.004	0.996	0.000
C00.1 External lower lip	0.004	0.996	0.000
C00.0 External upper lip	0.004	0.996	0.000
C11.9 Nasopharynx, unspecified	0.004	0.996	0.000
C11.8 Overlapping lesion of nasopharynx	0.004	0.996	0.000
C11.3 Anterior wall of nasopharynx	0.004	0.996	0.000
C11.2 Lateral wall of nasopharynx	0.004	0.996	0.000
C11.1 Posterior wall of nasopharynx	0.004	0.996	0.000
C11.0 Superior wall of nasopharynx	0.004	0.996	0.000
E85.8 Other amyloidosis	0.004	0.996	0.000
E85.2 Heredofamilial amyloidosis, unspecified	0.004	0.996	0.000
E85.1 Neuropathic heredofamilial amyloidosis	0.004	0.996	0.000
E85.0 Nonneuropathic heredofamilial amyloidosis	0.004	0.996	0.000
G25.9 Extrapyramidal and movement disorder, unspecified	0.004	0.996	0.000
C06.9 Mouth, unspecified	0.004	0.996	0.000
E89.6 Postprocedural adrenocortical(-medullary) hypofunction	0.004	0.996	0.000
J20-J22 Other acute lower respiratory infections	0.004	0.996	0.000
E89.3 Postprocedural hypopituitarism	0.004	0.996	0.000
N31.9 Neuromuscular dysfunction of bladder, unspecified	0.004	0.996	0.000
T78.9 Adverse effect, unspecified	0.003	0.996	0.000
E89.9 Postprocedural endocrine and metabolic disorder, unspecified	0.003	0.996	0.000
E89.8 Other postprocedural endocrine and metabolic disorders	0.003	0.996	0.000
E89.5 Postprocedural testicular hypofunction	0.003	0.996	0.000
E89.1 Postprocedural hypoinsulinaemia	0.003	0.996	0.000
G25.8 Other specified extrapyramidal and movement disorders	0.004	0.996	0.000
Y41 Other systemic anti-infectives and antiparasitics	0.004	0.996	0.000
Y54 Agents primarily affecting water-balance and mineral and uric acid metabolism	0.004	0.996	0.000
Y40-Y59 Drugs, medicaments and biological substances causing adverse effects in therapeutic use	0.004	0.996	0.000
E85.9 Amyloidosis, unspecified	0.003	0.996	0.000
E89.4 Postprocedural ovarian failure	0.003	0.996	0.000
R18 Ascites	0.004	0.996	0.000
M54.92 Dorsalgia, unspecified (Cervical region)	0.003	0.996	0.000
C07 Malignant neoplasm of parotid gland	0.003	0.996	0.000
G25.2 Other specified forms of tremor	0.003	0.996	0.000
C04.8 Overlapping lesion of floor of mouth	0.003	0.996	0.000
C04.1 Lateral floor of mouth	0.003	0.996	0.000
C04.0 Anterior floor of mouth	0.003	0.996	0.000
S01.5 Open wound of lip and oral cavity	0.000	0.996	0.003
J20.8 Acute bronchitis due to other specified organisms	0.003	0.997	0.000
C14.8 Overlapping lesion of lip, oral cavity and pharynx	0.003	0.997	0.000
C14.2 Waldeyer's ring	0.003	0.997	0.000
G25.5 Other chorea	0.003	0.997	0.000
M54.95 Dorsalgia, unspecified (Thoracolumbar region)	0.003	0.997	0.000
J20 Acute bronchitis	0.003	0.997	0.000
M54.3 Sciatica	0.003	0.997	0.000
S00.9 Superficial injury of head, part unspecified	0.003	0.997	0.000
Y41.5 Antiviral drugs	0.003	0.997	0.000
Y54.4 Loop [high-ceiling] diuretics	0.003	0.997	0.000
M54.99 Dorsalgia, unspecified (Site unspecified)	0.003	0.997	0.000
T78.3 Angioneurotic oedema	0.003	0.997	0.000
Y42.7 Androgens and anabolic congeners	0.003	0.997	0.000
G25.6 Drug-induced tics and other tics of organic origin	0.003	0.997	0.000
G25.4 Drug-induced chorea	0.003	0.997	0.000
G25.1 Drug-induced tremor	0.003	0.997	0.000
Y54.0 Mineralocorticoids	0.003	0.997	0.000
M54.93 Dorsalgia, unspecified (Cervicothoracic region)	0.003	0.997	0.000
M54.91 Dorsalgia, unspecified (Occipito-atlanto-axial region)	0.003	0.997	0.000
I22.9 Subsequent myocardial infarction of unspecified site	0.003	0.997	0.000
Y54.1 Mineralocorticoid antagonists [aldosterone antagonists]	0.003	0.997	0.000
J94 Other pleural conditions	0.003	0.997	0.000
Y41.0 Sulphonamides	0.003	0.997	0.000
M54.39 Sciatica (Site unspecified)	0.003	0.997	0.000
E89.2 Postprocedural hypoparathyroidism	0.003	0.997	0.000
Y41.8 Other specified systemic anti-infectives and antiparasitics	0.003	0.997	0.000
Y55 Agents primarily acting on smooth and skeletal muscles and the respiratory system	0.003	0.997	0.000
M54.90 Dorsalgia, unspecified (Multiple sites in spine)	0.003	0.997	0.000
Y54.7 Agents affecting calcification	0.003	0.997	0.000
Y44 Agents primarily affecting blood constituents	0.003	0.997	0.000
Y54.8 Agents affecting uric acid metabolism	0.003	0.997	0.000
Y42 Hormones and their synthetic substitutes and antagonists, not elsewhere classified	0.003	0.997	0.000
N60.0 Solitary cyst of breast	0.003	0.997	0.000
Y49 Psychotropic drugs, not elsewhere classified	0.003	0.997	0.000
N05.2 Diffuse membranous glomerulonephritis	0.003	0.997	0.000
E85.4 Organ-limited amyloidosis	0.002	0.997	0.000
J94.9 Pleural condition, unspecified	0.003	0.997	0.000
Y60.0 During surgical operation	0.000	0.997	0.003
I27.2 Other secondary pulmonary hypertension	0.003	0.997	0.000
Y41.1 Antimycobacterial drugs	0.003	0.997	0.000
Y58 Bacterial vaccines	0.003	0.997	0.000
Y41.9 Systemic anti-infective and antiparasitic, unspecified	0.003	0.997	0.000
Y41.4 Anthelminthics	0.003	0.997	0.000
Y41.3 Other antiprotozoal drugs	0.003	0.997	0.000
Y41.2 Antimalarials and drugs acting on other blood protozoa	0.003	0.997	0.000
Y54.9 Mineral salts, not elsewhere classified	0.003	0.997	0.000
Y54.6 Electrolytic, caloric and water-balance agents	0.003	0.997	0.000
Y54.2 Carbonic-anhydrase inhibitors	0.003	0.997	0.000
Y59 Other and unspecified vaccines and biological substances	0.003	0.997	0.000
Y50 Central nervous system stimulants, not elsewhere classified	0.003	0.997	0.000
M54.18 Radiculopathy (Sacral and sacrococcygeal region)	0.003	0.997	0.000
C04.9 Floor of mouth, unspecified	0.002	0.997	0.000
Y49.5 Other antipsychotics and neuroleptics	0.003	0.997	0.000
G20 Parkinson's disease	0.003	0.997	0.000
X58.9 Unspecified place	0.003	0.997	0.000
M54.97 Dorsalgia, unspecified (Lumbosacral region)	0.003	0.997	0.000
C14.0 Pharynx, unspecified	0.002	0.997	0.000
T78.0 Anaphylactic shock due to adverse food reaction	0.003	0.997	0.000
Y54.3 Benzothiadiazine derivatives	0.003	0.997	0.000
Y53 Agents primarily affecting the gastro-intestinal system	0.003	0.997	0.000
G25.3 Myoclonus	0.003	0.997	0.000
J20.7 Acute bronchitis due to echovirus	0.003	0.997	0.000
J20.6 Acute bronchitis due to rhinovirus	0.003	0.997	0.000
J20.5 Acute bronchitis due to respiratory syncytial virus	0.003	0.997	0.000
J20.4 Acute bronchitis due to parainfluenza virus	0.003	0.997	0.000
J20.3 Acute bronchitis due to coxsackie virus	0.003	0.997	0.000
J20.2 Acute bronchitis due to streptococcus	0.003	0.997	0.000
J20.1 Acute bronchitis due to Haemophilus influenzae	0.003	0.997	0.000
J20.0 Acute bronchitis due to Mycoplasma pneumoniae	0.003	0.997	0.000
Y48 Anaesthetics and therapeutic gases	0.003	0.997	0.000
M54.35 Sciatica (Thoracolumbar region)	0.003	0.997	0.000
M54.34 Sciatica-Thoracic	0.003	0.997	0.000
M54.33 Sciatica-Cervicothoracic	0.003	0.997	0.000
M54.32 Sciatica-Cervical	0.003	0.997	0.000
M54.31 Sciatica-Occipit-atl-axl	0.003	0.997	0.000
M54.30 Sciatica (Multiple sites in spine)	0.003	0.997	0.000
J94.1 Fibrothorax	0.003	0.997	0.000
M54.94 Dorsalgia, unspecified (Thoracic region)	0.003	0.997	0.000
Y40.9 Systemic antibiotic, unspecified	0.003	0.997	0.000
M54 Dorsalgia	0.003	0.997	0.000
Y42.3 Insulin and oral hypoglycaemic [antidiabetic] drugs	0.003	0.997	0.000
Y55.1 Skeletal muscle relaxants [neuromuscular blocking agents]	0.003	0.997	0.000
Y84.8 Other medical procedures	0.003	0.997	0.000
J21 Acute bronchiolitis	0.002	0.997	0.000
Y44.2 Anticoagulants	0.003	0.997	0.000
G20-G26 Extrapyramidal and movement disorders	0.003	0.997	0.000
E83 Disorders of mineral metabolism	0.003	0.997	0.000
Y47 Sedatives, hypnotics and antianxiety drugs	0.002	0.997	0.000
Y45.0 Opioids and related analgesics	0.003	0.997	0.000
M54.1 Radiculopathy	0.003	0.997	0.000
Y46 Antiepileptics and anti-Parkinsonism drugs	0.002	0.997	0.000
M54.23 Cervicalgia (Cervicothoracic region)	0.002	0.997	0.000
S01.7 Multiple open wounds of head	0.000	0.997	0.002
Y43.1 Antineoplastic antimetabolites	0.002	0.997	0.000
Y51 Drugs primarily affecting the autonomic nervous system	0.002	0.997	0.000
J94.0 Chylous effusion	0.002	0.997	0.000
S70.1 Contusion of thigh	0.002	0.997	0.000
Y43 Primarily systemic agents	0.002	0.997	0.000
O72.2 Delayed and secondary postpartum haemorrhage	0.000	0.997	0.002
Y55.6 Antiasthmatics, not elsewhere classified	0.002	0.997	0.000
M54.2 Cervicalgia	0.002	0.998	0.000
Y44.9 Other and unspecified agents affecting blood constituents	0.002	0.998	0.000
Y44.7 Plasma substitutes	0.002	0.998	0.000
Y44.6 Natural blood and blood products	0.002	0.998	0.000
Y44.5 Thrombolytic drugs	0.002	0.998	0.000
Y44.4 Antithrombotic drugs [platelet-aggregation inhibitors]	0.002	0.998	0.000
Y44.3 Anticoagulant antagonists, vitamin K and other coagulants	0.002	0.998	0.000
Y44.1 Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations	0.002	0.998	0.000
Y44.0 Iron preparations and other anti-hypochromic-anaemia preparations	0.002	0.998	0.000
Y55.7 Other and unspecified agents primarily acting on the respiratory system	0.002	0.998	0.000
Y55.5 Anticommon cold drugs	0.002	0.998	0.000
Y55.4 Expectorants	0.002	0.998	0.000
Y55.3 Antitussives	0.002	0.998	0.000
Y55.2 Other and unspecified agents primarily acting on muscles	0.002	0.998	0.000
Y55.0 Oxytocic drugs	0.002	0.998	0.000
Y42.8 Other and unspecified hormones and their synthetic substitutes	0.002	0.998	0.000
M54.8 Other dorsalgia	0.002	0.998	0.000
Y42.9 Other and unspecified hormone antagonists	0.002	0.998	0.000
Y42.4 Oral contraceptives	0.002	0.998	0.000
Y42.2 Antithyroid drugs	0.002	0.998	0.000
Y49.9 Psychotropic drug, unspecified	0.002	0.998	0.000
Y49.8 Other psychotropic drugs, not elsewhere classified	0.002	0.998	0.000
Y49.7 Psychostimulants with abuse potential	0.002	0.998	0.000
Y49.6 Psychodysleptics [hallucinogens]	0.002	0.998	0.000
Y49.4 Butyrophenone and thioxanthene neuroleptics	0.002	0.998	0.000
Y49.3 Phenothiazine antipsychotics and neuroleptics	0.002	0.998	0.000
Y49.1 Monoamine-oxidase-inhibitor antidepressants	0.002	0.998	0.000
M54.28 Cervicalgia-Sacral/sacrococ	0.002	0.998	0.000
Y48.2 Other and unspecified general anaesthetics	0.002	0.998	0.000
X58 Exposure to other specified factors	0.002	0.998	0.000
Y52 Agents primarily affecting the cardiovascular system	0.002	0.998	0.000
Y58.0 BCG vaccine	0.002	0.998	0.000
Y56 Topical agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs	0.002	0.998	0.000
Y45 Analgesics, antipyretics and anti-inflammatory drugs	0.002	0.998	0.000
J20.9 Acute bronchitis, unspecified	0.002	0.998	0.000
G23 Other degenerative diseases of basal ganglia	0.002	0.998	0.000
H58.8 Visual disturbances in diseases classified elsewhere	0.002	0.998	0.000
Y58.9 Other and unspecified bacterial vaccines	0.002	0.998	0.000
Y58.8 Mixed bacterial vaccines, except combinations with a pertussis component	0.002	0.998	0.000
Y58.6 Pertussis vaccine, including combinations with a pertussis component	0.002	0.998	0.000
Y58.5 Diphtheria vaccine	0.002	0.998	0.000
Y58.4 Tetanus vaccine	0.002	0.998	0.000
Y58.3 Plague vaccine	0.002	0.998	0.000
Y58.2 Cholera vaccine	0.002	0.998	0.000
Y58.1 Typhoid and paratyphoid vaccine	0.002	0.998	0.000
Y49.0 Tricyclic and tetracyclic antidepressants	0.002	0.998	0.000
Y50.9 Central nervous system stimulant, unspecified	0.002	0.998	0.000
Y50.8 Other central nervous system stimulants	0.002	0.998	0.000
Y50.2 Methylxanthines, not elsewhere classified	0.002	0.998	0.000
Y50.1 Opioid receptor antagonists	0.002	0.998	0.000
Y50.0 Analeptics	0.002	0.998	0.000
Y59.9 Vaccine or biological substance, unspecified	0.002	0.998	0.000
Y59.8 Other specified vaccines and biological substances	0.002	0.998	0.000
Y59.3 Immunoglobulin	0.002	0.998	0.000
Y59.2 Protozoal vaccines	0.002	0.998	0.000
Y59.1 Rickettsial vaccines	0.002	0.998	0.000
Y59.0 Viral vaccines	0.002	0.998	0.000
Y57 Other and unspecified drugs and medicaments	0.002	0.998	0.000
M54.86 Other dorsalgia (Lumbar region)	0.002	0.998	0.000
Y84.9 Medical procedure, unspecified	0.002	0.998	0.000
Y42.1 Thyroid hormones and substitutes	0.002	0.998	0.000
Y52.1 Calcium-channel blockers	0.002	0.998	0.000
M54.16 Radiculopathy (Lumbar region)	0.002	0.998	0.000
Y51.6 @-Adrenoreceptor antagonists, not elsewhere classified	0.002	0.998	0.000
Y54.5 Other diuretics	0.002	0.998	0.000
M54.17 Radiculopathy (Lumbosacral region)	0.002	0.998	0.000
M54.38 Sciatica (Sacral and sacrococcygeal region)	0.002	0.998	0.000
N80.3 Endometriosis of pelvic peritoneum	0.002	0.998	0.000
V78.1 Passenger injured in nontraffic accident	0.002	0.998	0.000
Y48.5 Therapeutic gases	0.002	0.998	0.000
Y48.1 Parenteral anaesthetics	0.002	0.998	0.000
Y48.0 Inhaled anaesthetics	0.002	0.998	0.000
Y53.9 Agent primarily affecting the gastro-intestinal system, unspecified	0.002	0.998	0.000
Y53.8 Other agents primarily affecting the gastro-intestinal system	0.002	0.998	0.000
Y53.7 Emetics	0.002	0.998	0.000
Y53.6 Antidiarrhoeal drugs	0.002	0.998	0.000
Y53.5 Digestants	0.002	0.998	0.000
Y53.3 Saline and osmotic laxatives	0.002	0.998	0.000
Y53.2 Stimulant laxatives	0.002	0.998	0.000
Y53.0 Histamine H2-receptor antagonists	0.002	0.998	0.000
T66-T78 Other and unspecified effects of external causes	0.002	0.998	0.000
M54.0 Panniculitis affecting regions of neck and back	0.002	0.998	0.000
Y42.0 Glucocorticoids and synthetic analogs	0.002	0.998	0.000
Y53.1 Other antacids and anti-gastric-secretion drugs	0.002	0.998	0.000
Y84 Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure	0.002	0.998	0.000
G23.1 Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]	0.002	0.998	0.000
Y84.2 Radiological procedure and radiotherapy	0.002	0.998	0.000
N05 Unspecified nephritic syndrome	0.002	0.998	0.000
J21.8 Acute bronchiolitis due to other specified organisms	0.002	0.998	0.000
J21.1 Acute bronchiolitis due to human metapneumovirus	0.002	0.998	0.000
J21.0 Acute bronchiolitis due to respiratory syncytial virus	0.002	0.998	0.000
N05.9 Unspecified	0.002	0.998	0.000
Y42.6 Antigonadotrophins, antioestrogens, antiandrogens, not elsewhere classified	0.002	0.998	0.000
Y52.0 Cardiac-stimulant glycosides and drugs of similar action	0.002	0.998	0.000
M70.65 Trochanteric bursitis-Pelvic/Thigh	0.002	0.998	0.000
G21 Secondary Parkinsonism	0.002	0.998	0.000
G26 Extrapyramidal and movement disorders in diseases classified elsewhere	0.002	0.998	0.000
G22 Parkinsonism in diseases classified elsewhere	0.002	0.998	0.000
D04.3 Skin of other and unspecified parts of face	0.000	0.998	0.002
E83.9 Disorder of mineral metabolism, unspecified	0.002	0.998	0.000
E83.8 Other disorders of mineral metabolism	0.002	0.998	0.000
E83.2 Disorders of zinc metabolism	0.002	0.998	0.000
E83.0 Disorders of copper metabolism	0.002	0.998	0.000
Y47.9 Sedative, hypnotic and antianxiety drug, unspecified	0.002	0.998	0.000
Y47.8 Other sedatives, hypnotics and antianxiety drugs	0.002	0.998	0.000
Y47.5 Mixed sedatives and hypnotics, not elsewhere classified	0.002	0.998	0.000
Y47.4 Bromine compounds	0.002	0.998	0.000
Y47.3 Paraldehyde	0.002	0.998	0.000
Y47.2 Chloral derivatives	0.002	0.998	0.000
Y47.0 Barbiturates, not elsewhere classified	0.002	0.998	0.000
Y53.4 Other laxatives	0.002	0.998	0.000
M54.15 Radiculopathy (Thoracolumbar region)	0.002	0.998	0.000
M54.14 Radiculopathy (Thoracic region)	0.002	0.998	0.000
M54.13 Radiculopathy (Cervicothoracic region)	0.002	0.998	0.000
M54.11 Radiculopathy (Occipito-atlanto-axial region)	0.002	0.998	0.000
M54.10 Radiculopathy (Multiple sites in spine)	0.002	0.998	0.000
Y48.4 Anaesthetic, unspecified	0.002	0.998	0.000
D22.1 Melanocytic naevi of eyelid, including canthus	0.000	0.998	0.002
J94.8 Other specified pleural conditions	0.002	0.998	0.000
Y46.8 Antispasticity drugs	0.002	0.998	0.000
Y46.7 Anti-Parkinsonism drugs	0.002	0.998	0.000
Y46.5 Valproic acid	0.002	0.998	0.000
Y46.3 Deoxybarbiturates	0.002	0.998	0.000
Y46.1 Oxazolidinediones	0.002	0.998	0.000
Y46.0 Succinimides	0.002	0.998	0.000
Y51.9 Other and unspecified drugs primarily affecting the autonomic nervous system	0.002	0.998	0.000
Y51.8 Centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified	0.002	0.998	0.000
Y51.5 Predominantly Beta-adrenoreceptor agonists, not elsewhere classified	0.002	0.998	0.000
Y51.4 Predominantly Alpha-adrenoreceptor agonists, not elsewhere classified	0.002	0.998	0.000
Y51.2 Ganglionic blocking drugs, not elsewhere classified	0.002	0.998	0.000
Y51.1 Other parasympathomimetics [cholinergics]	0.002	0.998	0.000
Y51.0 Anticholinesterase agents	0.002	0.998	0.000
X58-X59 Accidental exposure to other and unspecified factors	0.002	0.998	0.000
E89.0 Postprocedural hypothyroidism	0.002	0.998	0.000
Y43.9 Primarily systemic agent, unspecified	0.002	0.998	0.000
Y43.8 Other primarily systemic agents, not elsewhere classified	0.002	0.998	0.000
Y43.6 Enzymes, not elsewhere classified	0.002	0.998	0.000
Y43.5 Acidifying and alkalising agents	0.002	0.998	0.000
Y43.2 Antineoplastic natural products	0.002	0.998	0.000
Y49.2 Other and unspecified antidepressants	0.002	0.998	0.000
Y51.3 Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified	0.002	0.998	0.000
Y57.5 X-ray contrast media	0.002	0.998	0.000
M54.27 Cervicalgia-Lumbosacral	0.002	0.998	0.000
M54.26 Cervicalgia-Lumbar	0.002	0.998	0.000
M54.25 Cervicalgia-Thoracolumbar	0.002	0.998	0.000
M54.24 Cervicalgia-Thoracic	0.002	0.998	0.000
M54.21 Cervicalgia (Occipito-atlanto-axial region)	0.002	0.998	0.000
M54.20 Cervicalgia-Mult site	0.002	0.998	0.000
Y46.2 Hydantoin derivatives	0.002	0.998	0.000
M54.88 Other dorsalgia (Sacral and sacrococcygeal region)	0.002	0.998	0.000
M54.87 Other dorsalgia (Lumbosacral region)	0.002	0.998	0.000
M54.85 Other dorsalgia (Thoracolumbar region)	0.002	0.998	0.000
M54.84 Other dorsalgia (Thoracic region)	0.002	0.998	0.000
M54.83 Other dorsalgia (Cervicothoracic region)	0.002	0.998	0.000
M54.82 Other dorsalgia (Cervical region)	0.002	0.998	0.000
M54.81 Other dorsalgia (Occipito-atlanto-axial region)	0.002	0.998	0.000
M54.80 Other dorsalgia (Multiple sites in spine)	0.002	0.998	0.000
Y52.4 Angiotensin-converting-enzyme inhibitors	0.002	0.998	0.000
R40.0 Somnolence	0.002	0.998	0.000
X59 Exposure to unspecified factor	0.002	0.998	0.000
X10.0 Home	0.002	0.998	0.000
X58.8 Other specified place	0.002	0.998	0.000
X58.0 Home	0.002	0.998	0.000
X58.7 Farm	0.002	0.998	0.000
X58.6 Industrial and construction area	0.002	0.998	0.000
X58.5 Trade and service area	0.002	0.998	0.000
X58.4 Street and highway	0.002	0.998	0.000

This table lists the top 500 terms ordered by p(effect).

The full results table can be downloaded from this page.

The TreeWAS Database is the result of research conducted at the Oxford Big Data Institute at the University of Oxford.

This research has been conducted using the UK Biobank Resource (application number 10625). This work uses data provided by patients and collected by the NHS as part of their care and support.

This research has been conducted with the support of the Wellcome Trust (100956/Z/13/Z and 090532/Z/09/Z and 100308/Z/12/Z), the Danish National Research Foundation, Takeda, the Medical Research Council (MC_UU_12010/3), the Oak Foundation (OCAY-15-520), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Wellcome Trust/Royal Society (204290/Z/16/Z) and the Li Ka Shing Foundation.

Variant-specific associations